For U.S. healthcare professionals.

Cost Benefits

A key factor affecting cost is the surfactant’s first-dose regimen, based on weight, combined with vial sizes available.

29% fewer vials of Infasurf^® (calfactant) needed on the initial dose than Curosurf^® (poractant alfa).

Infasurf® (calfactant) - Each Dose¹

Curosurf® (poractant alfa) - Initial Dose²

Patient Demographics of Treated Infants 2005-2010*

Birth weight determines the dose required.

6% ≤ 600g

21% 601 – 1000g

10% 1001 – 1200g

28% 1201 – 1800g

8% 1801 – 2000g

11% 2001 – 2400g

16% 2401 – 3000g

All patients receive an initial dose
Fewer vials have shown to lower total surfactant costs³

The Science Efficacy

*Calculation of cohorts is based upon a large national sample which described birth weight distribution of 51,282 surfactant-treated patients from 322 neonatal intensive care units over six years.⁴ Birth weight cohorts were defined where a change in vial size or vial count is required by each drug’s respective prescribing information.

There are no prospective, randomized clinical trials comparing Infasurf® and Curosurf® with respect to safety or efficacy.

Infasurf is indicated for the prevention of Respiratory Distress Syndrome (RDS) in premature infants at high risk for RDS and for the treatment of premature infants who develop RDS. Infasurf decreases the incidence of RDS, mortality due to RDS, and air leaks associated with RDS.

Prophylaxis

Prophylaxis therapy at birth with Infasurf is indicated for premature infants <29 weeks of gestational age at significant risk for RDS. Infasurf prophylaxis should be administered as soon as possible, preferably within 30 minutes after birth.

Treatment

Infasurf therapy is indicated for infants ≤72 hours of age with RDS (confirmed by clinical and radiologic findings) and requiring endotracheal intubation.

Infasurf is intended for intratracheal use only. THE ADMINISTRATION OF EXOGENOUS SURFACTANTS, INCLUDING INFASURF, OFTEN RAPIDLY IMPROVES OXYGENATION AND LUNG COMPLIANCE. Following administration of Infasurf, patients should be carefully monitored so that oxygen therapy and ventilatory support can be modified in response to changes in respiratory status.

Infasurf therapy is not a substitute for neonatal intensive care. Optimal care of premature infants at risk for RDS and newborn infants with RDS who need endotracheal intubation requires an acute care unit organized, staffed, equipped, and experienced with intubation, ventilator management, and general care of these patients.

TRANSIENT EPISODES OF REFLUX OF INFASURF INTO THE ENDOTRACHEAL TUBE, CYANOSIS, BRADYCARDIA, OR AIRWAY OBSTRUCTION HAVE OCCURRED DURING THE DOSING PROCEDURES that required stopping Infasurf and taking appropriate measures to alleviate the condition. After the patient is stable, dosing can proceed with appropriate monitoring.

An increased proportion of patients with both intraventricular hemorrhage (IVH) and periventricular leukomalacia (PVL) was observed in Infasurf-treated infants in the Infasurf-Exosurf Neonatal controlled trials. These observations were not associated with increased mortality.

The most common adverse reactions associated with Infasurf dosing procedures in the controlled trials were cyanosis (65%), airway obstruction (39%), bradycardia (34%), reflux of surfactant into the endotracheal tube (21%), requirement for manual ventilation (16%), and reintubation (3%). These events were generally transient and not associated with serious complications or death.

The incidence of common complications of prematurity and RDS in the four controlled Infasurf trials are presented in the Table. Prophylaxis and treatment study results for each surfactant are combined.

See full prescribing information.

References: 1. Infasurf^® (calfactant) Intratracheal Suspension Prescribing Information, ONY Biotech, March 2018. 2. Curosurf^® (poractant alfa) Intratracheal Suspension Prescribing Information, Chiesi USA, Inc. December 2014. 3. Zayek MM, Eyal FG, Smith RC. Comparison of the pharmacoeconomics of calfactant and poractant alfa in surfactant replacement therapy. JPPT. 2018;23(2):146-151. 4. Trembath A, Hornik CP, Clark R, et al. Comparative effectiveness of surfactant preparations in premature infants. J Pediatr. 2013;163(4):955-960.

Cost Benefits

29% fewer vials of Infasurf® (calfactant) needed on the initial dose than Curosurf® (poractant alfa).

Patient Demographics of Treated Infants 2005-2010*

29% fewer vials of Infasurf^® (calfactant) needed on the initial dose than Curosurf^® (poractant alfa).